22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
At what point does a company’s application of its anti-fraternization policy become sex discriminat...
Read More >
The coronavirus (COVID-19) pandemic has shut down non-essential construction projects in numerous st...
Read More >
Your home base for all things healthcare compliance. The Compliance Institute offers the latest upda...
Read More >
The IRS’s informal FAQs provide comfort that an acquirer, including affiliated companies treated as...
Read More >
“Big data” has become one of the hottest subjects for antitrust enforcers around the globe. There ...
Read More >
In 2016, the EEOC revised its EEO-1 form that collects pay data from employers with 100 or more empl...
Read More >